3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Brain Neoplasms
6
Breast Neoplasms
4
Recurrence
2
Oligodendroglioma
2
Meningeal Carcinomatosis
2
Glioblastoma
2
Astrocytoma
2
Triple Negative Breast Neoplasms
1
Meningeal Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
Carboplatin
367
Pemetrexed
308
pembrolizumab
302
Cisplatin
242
Paclitaxel
230
Docetaxel
199
Gemcitabine
130
Nivolumab
121
Erlotinib Hydrochloride
114
Bevacizumab
85
osimertinib
78
atezolizumab
65
durvalumab
58
Cetuximab
57
130-nm albumin-bound paclitaxel
56
Gefitinib
52
Ipilimumab
46
Afatinib
38
Drug Therapy
33
Cyclophosphamide
30
Crizotinib
30
Albumin-Bound Paclitaxel
30
Vinorelbine
28
cemiplimab
26
tislelizumab
25
avelumab
23
icotinib
22
Radiotherapy
22
capmatinib
21
Oxaliplatin
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Non-Small-Cell Lung
×
paclitaxel-Angiopep-2 conjugate
×
Clear all
NCT01497665
2019-01-22
GRABM-L
Angiochem Inc
Phase 2
Terminated
16 enrolled
7 charts